IPC Indice de Precios Y Cotizaciones Ends 0.68% Lower at 55415.69 — Data Talk
The IPC Indice de Precios Y Cotizaciones is down 381.56 points or 0.68% today to 55415.69
--Down for four consecutive trading days
--Down 1414.63 points or 2.49% over the last four trading days
--Largest four-day point and percentage decline since Monday, April 15, 2024
--Longest losing streak since Thursday, Jan. 18, 2024, when the market fell for four straight trading days
--Down seven of the past eight trading days
--Off 5.61% from its record close of 58711.87 hit Wednesday, Feb. 7, 2024
--Lowest closing value since Tuesday, March 12, 2024
--Off 5.61% from its 52-week high of 58711.87 hit Wednesday, Feb. 7, 2024
--Up 14.98% from its 52-week low of 48197.88 hit Monday, Oct. 23, 2023
--Rose 2.04% from 52 weeks ago
--Off 5.61% from its 2024 closing high of 58711.87 hit Wednesday, Feb 7, 2024
--Up 1.29% from its 2024 closing low of 54707.89 hit Thursday, Jan. 18, 2024
--Month-to-date it is down 3.40%
--Year-to-date it is down 1970.56 points or 3.43%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 17, 2024 17:14 ET (21:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track